Answers are grounded in this paper and cite their sources.
Background and Objectives: Omega-3 and other polyunsaturated fatty acid (PUFA) interventions are used for dry eye disease (DED), yet reviews disagree about efficacy. We synthesised review-level evidence on clinical effects, methodological confidence and primary-study overlap. Materials and Methods: We searched Embase, Ovid MEDLINE, Ovid Emcare and the Cochrane Library for systematic reviews published from 2016 to June 2026 using title/abstract free-text terms. Two reviewers independently screened records and appraised reviews using AMSTAR 2. Findings were synthesised narratively; overlap was measured using corrected covered area (CCA). The review was retrospectively registered with the Open Science Framework. Results: Of 920 retrieved records, 542 were screened, 16 full texts assessed and 12 reviews included. Reported benefits were most frequent for symptoms and tear break-up time, but objective signs were inconsistent and several pooled estimates had extreme heterogeneity. Two reviews were rated high confidence, three moderate, one low and six critically low. Fifty unique primary studies contributed 155 occurrences (CCA 19.1%, very high overlap). The high-confidence reviews suggested small or uncertain benefits; a conservative AMSTAR 2 sensitivity analysis further reduced confidence in several reviews. Conclusions: The evidence does not support routine omega-3/PUFA treatment across DED phenotypes. Supplementation may be discussed as an optional adjunct, but statistically favourable results do not necessarily indicate clinically meaningful improvement. More rigorous phenotype-specific trials with standardised formulations, comparators and patient-centred outcomes are needed.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: